1-4 of 4
Gregory Finn
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

MagnetisMM-32: Evaluation of Elranatamab Vs EPd, PVd, or Kd in Patients with Relapsed or Refractory Multiple Myeloma and Prior Anti-CD38-Directed Therapy

Steven Schuster, Satoshi Ito, Margaret Hoyle, Anne Yver, Fangxin Hong, Gregory Finn
Journal: Blood
Blood (2024) 144 (Supplement 1): 7013.
https://doi.org/10.1182/blood-2024-207377
Published: 2024
Journal Articles

Magnetismm-4: An Open Label, Phase 1B/2 Umbrella Study of Elranatamab in Combination with Other Anti-Cancer Treatments for Patients with Multiple Myeloma

Ola Landgren, Dickran Kazandjian, Ashleigh O'Connell, Gregory Finn, Noopur Raje
Journal: Blood
Blood (2022) 140 (Supplement 1): 10172–10173.
https://doi.org/10.1182/blood-2022-166854
Published: 2022
Journal Articles

Dose Optimization to Mitigate the Risk of CRS with Elranatamab in Multiple Myeloma

Mohamed Elmeliegy, Andrea Viqueira, Erik Vandendries, Anne Hickman, Jennifer Hibma, Hoi-Kei Lon, Joseph Piscitelli, Pooneh Soltantabar, Diane Wang, Sibo Jiang, Gregory Finn, Akos Czibere
Journal: Blood
Blood (2022) 140 (Supplement 1): 7174–7175.
https://doi.org/10.1182/blood-2022-169971
Published: 2022
Journal Articles

Elranatamab in Combination with Daratumumab for Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 3 Magnetismm-5 Study Safety Lead-in Cohort

Sebastian Grosicki, Ulf-Henrik Mellqvist, Łukasz Pruchniewski, Jacob Crafoord, Suzanne Trudel, Chang-Ki Min, Darrell White, Adrian Alegre, Markus Hansson, Takashi Ikeda, Kazutaka Sunami, Eric Leip, Arthur Kudla, Gregory Finn, Youngil Koh
Journal: Blood
Blood (2022) 140 (Supplement 1): 4407–4408.
https://doi.org/10.1182/blood-2022-162738
Published: 2022